PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1720041
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1720041
Cell Therapy Technologies Market size was valued at US$ 3,920.33 Million in 2024, expanding at a CAGR of 11.50% from 2025 to 2032.
Cell therapy technologies encompass the tools, techniques, and platforms used to develop, manufacture, and deliver cell therapies for treating diseases. These technologies include cell isolation, expansion, genetic modification, and preservation methods. They enable the production of therapies like CAR-T cells, stem cell-based treatments, and regenerative medicine applications. Key advancements involve automation, bioreactors, gene-editing tools like CRISPR, and cryopreservation techniques. These technologies, used in oncology, neurology, and autoimmune disorders, enhance therapy scalability, efficiency, and regulatory compliance. The field is evolving to improve affordability and accessibility, driving innovation in personalised medicine and advanced therapeutic manufacturing.
Cell Therapy Technologies Market- Market Dynamics
Advancements in personalised medicine, increasing research and development efforts to propel market demand
The cell therapy technologies market is growing rapidly driven by advancements in personalized medicine, increased research and development, and significant investments in pharmaceutical and biotechnology companies. The rising demand for targeted and effective treatments, particularly in oncology, neurology, and autoimmune disorders, has driven wider adoption of cell-based therapies. One of the developments shaping the market in this field is CAR-T cell therapy, which involves genetically modifying a patient's immune cells to identify and attack cancer cells. This approach has shown remarkable success in treating certain blood cancers, leading to broader regulatory approvals and greater industry confidence. Key market players like Autolus are at the forefront of CAR-T innovation, with treatments such as Aucatzyl recently receiving FDA approval for acute lymphoblastic leukemia. These approvals reinforce the growing acceptance of cell-based therapies and encourage further investment in the sector. Advancements in cell isolation along with expansion, and genetic modification have also improved manufacturing efficiency, making large-scale production and commercialization more viable. The integration of automation and bioreactor systems has further streamlined development, reducing costs and improving accessibility for patients. Beyond oncology, cell therapy is also expanding into regenerative medicine, with promising applications in tissue repair, neurodegenerative diseases, and autoimmune disorders.
Cell Therapy Technologies Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 11.50% over the forecast period (2025-2032)
Based on product type segmentation, Consumables & Accessories was predicted to show maximum market share in the year 2024
Based on Workflow segmentation, Separation was the leading Workflow in 2024
Based on cell Type segmentation, T-cells was the leading cell Type in 2024
On the basis of region, North America was the leading revenue generator in 2024
The Global Cell Therapy Technologies Market is segmented on the basis of Product Type, Workflow, Cell Type, Technology, and Region.
The market is divided into four categories based on product type: Raw Materials, Instruments, Software, and Consumables & Accessories. In 2024, the consumables segment dominated the cell therapy technologies market, driven by the strong demand for culture media, reagents, and growth factors essential for research and production. The expanding adoption of cell-based therapies, advancements in bioprocessing techniques, and growing clinical trials have further propelled market growth. The recurring use of consumables in manufacturing and research makes this segment a key revenue contributor.
The market is divided into six categories based on Workflow: Separation, Expansion, Apheresis, Fill- Finish, Cryopreservation and Others. The separation segment emerged as the market leader in 2024 and is projected to experience the fastest growth in the coming years. The increasing need for efficiency, scalability, and cost reduction in cell therapy manufacturing is fueling this expansion. Automation of key processes, such as cell expansion and separation, plays a crucial role in this trend. In February 2024, Multiply Labs and Thermo Fisher Scientific strengthened their partnership to automate these steps, enhancing workflows, improving efficiency, and accelerating production while maintaining quality control. This automation is expected to streamline manufacturing, reduce costs, and support the rising demand for cell therapies.
Cell Therapy Technologies Market- Geographical Insights
The market is divided into five regions: North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America led the global cell therapy technologies market, primarily due to the rising prevalence of cancer, diabetes, and heart diseases. The increasing demand for advanced cell-based treatments has driven the need for essential raw materials, software, and instruments. A well-established healthcare system and transparent regulatory frameworks have facilitated the region's development and commercialisation of cell therapies. This favourable environment has attracted significant investments from governmental and private entities, fostering research and innovation.
Cell therapy technologies market companies are adopting various strategies to strengthen their capabilities, expand their pipelines, and enhance scalability. A key trend is the growing interest in mRNA technology, accelerated by the success of mRNA vaccines during the COVID-19 pandemic. Companies like BioNTech and Moderna now focus on personalised mRNA cancer vaccines, leveraging the technology's adaptability to boost immune responses against diseases. This shift highlights the potential of mRNA in advancing cell-based treatments. Strategic acquisitions play a crucial role in market expansion. In November 2024, Roche acquired Poseida Therapeutics for up to USD 1.5 billion to enhance its oncology, immunology, and neurology pipeline. Poseida specialises in CAR-T cell therapies, and this acquisition is expected to drive the development of next-generation off-the-shelf CAR-T treatments that offer improved scalability, potency, and safety. Similarly, in February 2024, AstraZeneca acquired Gracell Biotechnologies for up to USD 1.2 billion, aligning with its strategy to launch 20 new medicines by 2030, with a strong focus on innovative cell therapy solutions. Investments in manufacturing infrastructure are also a key strategy to meet rising demand.
In December 2024, BioCentriq invested USD 12 million in a new cell therapy manufacturing facility in Princeton, NJ, which will be its headquarters. This expansion aims to strengthen cell therapy development and production capabilities, ensuring scalability and efficiency in bringing advanced therapies to market.